Background and Aims: A biosimilar version of infliximab [CT-P13/Remsima®] recently
entered the European market. The clinical data on its use in inflammatory bowel disease …

Background & Aims There is evidence that it is safe and effective for patients with
inflammatory bowel diseases (IBD) to switch from maintenance therapy with an original …

Background: The first monoclonal antibody biosimilar to be used in clinical practice is the
tumour necrosis factor-alpha inhibitor Remsima®(CT-P13). The drug is approved for all …

Aim To review the effectiveness and safety of switching from an originator anti-TNF
(Remicade®) to a biosimilar (CT-P13) in patients with inflammatory bowel disease (IBD) …

Background The infliximab biosimilar has entered daily inflammatory bowel disease (IBD)
practice. However, real-life outcomes beyond 1 year after switching are scarce. We aimed to …

Background: As the patents of originator biologics are expiring, biosimilar versions are
becoming available for the treatment of inflammatory bowel disease (IBD). However …

Background Limited data are available on long-term clinical outcomes regarding the switch
from Remicade® to the infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD) …

Abstract Background and Aims: The biosimilar of Remicade®, CT-P13, recently entered the
European market. Clinical data on switching from Remicade® to CT-P13 in inflammatory …

Background: Biosimilar infliximab (IFX) seems to have similar efficacy and safety to original
preparation in patients with inflammatory bowel diseases (IBD) who are naïve to anti-TNFa …

Background: The evidence on the efficacy and safety of biosimilar infliximab (IFX) in patients
with inflammatory bowel diseases (IBD) is sparse. Methods: Consecutive IBD patients …